Is trevogrumab available outside clinical trials?

No. Trevogrumab (REGN1033) is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals. It is currently in Phase 2 clinical trials (COURAGE trial) and is not commercially available. As a monoclonal antibody, it cannot be obtained from research peptide suppliers.

How does trevogrumab compare to bimagrumab?

Both target the myostatin pathway but differ in mechanism. Trevogrumab directly binds and neutralizes myostatin protein, while bimagrumab blocks the ActRII receptor that myostatin signals through. Trevogrumab is more selective (myostatin only) while bimagrumab also blocks activin A and other ligands. The COURAGE trial uses subcutaneous injection while bimagrumab requires IV infusion. Head-to-head comparison data is not available.

What did the COURAGE trial show?

At 26 weeks, adding trevogrumab to semaglutide preserved approximately 50% of the lean mass that would otherwise be lost during weight loss, while also increasing fat mass loss compared to semaglutide alone. Full 52-week results are pending. These results are similar in direction to the bimagrumab and apitegromab combination trial data.

Trevogrumab: Community Protocols & Reports

Aggregated community experiences, protocols, and stacking patterns

Anecdotal ReportsBased on 15 community reports

Community-Sourced Information

The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.

For peer-reviewed dosing protocols, see the clinical dosing guide.

Browse community protocols for all 130 peptides →

✓Reviewed byEditorial Team

📅Updated February 16, 2026

Unverified

📌TL;DR

•1 community protocols documented
•Evidence level: Anecdotal Reports
•Based on 15 community reports
•1 stacking patterns reported

Clinical vs. Community Protocol Differences

How community-reported protocols differ from clinical research protocols.

Aspect	Clinical Approach	Community Approach	Significance
Clinical Trial Only	Trevogrumab is in Phase 2 clinical trials (COURAGE trial) in combination with semaglutide for muscle preservation during weight loss. It is administered by subcutaneous injection in clinical settings.	Community interest exists primarily in research discussion forums and fitness communities following the obesity treatment pipeline. No community use protocols exist as the compound is only available in clinical trials.	high As a monoclonal antibody developed by Regeneron, trevogrumab is not available from research peptide suppliers. Community discussion is speculative and based on published trial data.
Selectivity Advantage	Trevogrumab selectively targets myostatin (GDF-8) without affecting GDF-11, activins, or BMPs. This selectivity distinguishes it from broader ActRIIB inhibitors like ACE-031 that caused vascular side effects.	Community discussions often compare trevogrumab favorably to earlier myostatin inhibitors, noting the improved selectivity that avoids vascular safety concerns. Comparisons with bimagrumab and apitegromab are frequent.	moderate The selective targeting of myostatin is seen as a key advantage in community discussions, though head-to-head comparisons between myostatin inhibitors have not been conducted.

Compare these community approaches with published research findings.

Community Protocols

COURAGE Phase 2 Trial Protocol

Niche

Route: Subcutaneous injection
Dose: Dose details from ongoing trial
Frequency: Every 4 weeks
Duration: 26 weeks (interim) to 52 weeks (full trial)

Phase 2 combination trial with semaglutide; not yet commercially available

Stacking Patterns

Trevogrumab + Semaglutide (COURAGE Protocol)

Niche

Investigational combination for preserving lean mass during GLP-1 mediated weight loss; 26-week data showed approximately 50% lean mass preservation

trevogrumab semaglutide

Check stack compatibility and review potential side effects before combining peptides.

Unlock community dosing protocols and stacking combos

See the exact doses, routes, and schedules 15+ self-experimenters report. Free with email.

150+ peptide profiles · 30+ comparisons · 18 research tools

Already subscribed?

Sources

Reddit r/Peptides|Trevogrumab and myostatin inhibitor pipeline discussions(accessed 2026-02-16)
Reddit r/loseit|GLP-1 combination therapies for muscle preservation discussions(accessed 2026-02-16)
American Diabetes Association|New GLP-1 Therapies Enhance Quality of Weight Loss(accessed 2026-02-16)

Community Evidence Overview#

This page presents aggregated community discussions and context for trevogrumab (REGN1033). This is not clinical evidence and should not be used as medical guidance.

Trevogrumab is an investigational monoclonal antibody currently in Phase 2 clinical trials. Community discussion is limited to research interest, pipeline tracking, and comparison with other myostatin pathway inhibitors. No community use protocols exist as the compound is only available through clinical trials.

The Muscle Preservation Race#

Trevogrumab is one of several myostatin pathway inhibitors being developed to address the lean mass loss that accompanies GLP-1 receptor agonist-mediated weight loss. Community discussions frequently compare the three leading candidates:

Compound	Developer	Mechanism	Route	Key Trial
Trevogrumab	Regeneron	Anti-myostatin mAb	SC injection	COURAGE
Bimagrumab	Eli Lilly	Anti-ActRII mAb	IV infusion	BELIEVE
Apitegromab	Scholar Rock	Anti-promyostatin mAb	IV infusion	EMBRAZE

All three have shown promising early data for lean mass preservation when combined with GLP-1 receptor agonists.

Community Interest Drivers#

The primary driver of community interest is the growing recognition that 30-40% of weight lost on GLP-1 agonists is lean mass (muscle), not fat. Trevogrumab's subcutaneous injection route (vs IV infusion for bimagrumab and apitegromab) is seen as a practical advantage for eventual commercial use.

Subscribe to see vendor options

Free access to verified vendor scores, pricing, and suppliers.